AtriCure Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) reported strong Q2 2024 financial results, with worldwide revenue reaching $116.3 million, a 15.2% increase year-over-year. The company generated positive cash flow of $8.1 million in Q2. U.S. revenue grew by 12.5% to $95.5 million, while international revenue surged by 29.4% to $20.7 million. Despite revenue growth, AtriCure reported a loss from operations of $7.2 million and a net loss per share of $0.17. The company updated its full-year 2024 revenue guidance to $456-$461 million, reflecting approximately 15% growth at the midpoint. AtriCure expects full-year 2024 Adjusted EBITDA of $26-$29 million and an adjusted loss per share of $0.74-$0.82.

Positive

• Worldwide revenue increased by 15.2% year-over-year to $116.3 million
• Positive cash flow generation of $8.1 million in Q2 2024
• U.S. revenue grew by 12.5% to $95.5 million
• International revenue surged by 29.4% to $20.7 million
• Updated full-year 2024 revenue guidance to $456-$461 million, reflecting 15% growth at midpoint
• Projected full-year 2024 Adjusted EBITDA increase of 34% to 49% over 2023

Negative

• Gross margin decreased by 168 basis points to 74.7% in Q2 2024
• Loss from operations increased to $7.2 million from $4.1 million in Q2 2023
• Net loss per share increased to $0.17 from $0.11 in Q2 2023
• Adjusted EBITDA decreased by $0.2 million compared to Q2 2023
• Adjusted loss per share increased to $0.17 from $0.12 in Q2 2023

Insights

Financial Analyst

AtriCure's Q2 2024 results demonstrate robust growth and operational efficiency. The company reported $116.3 million in worldwide revenue, marking a 15.2% year-over-year increase. This growth was primarily driven by strong performances in pain management, open AtriClip® franchises and international markets.

Key financial highlights include:

• U.S. revenue increased by 12.5% to $95.5 million
• International revenue grew by 29.4% to $20.7 million
• Gross profit rose to $86.8 million, though gross margin decreased by 168 basis points to 74.7%
• Operating loss widened to $7.2 million from $4.1 million in Q2 2023
• Adjusted EBITDA slightly decreased to $7.8 million

The company's ability to generate positive cash flow of $8.1 million in Q2 is noteworthy, indicating improved operational efficiency. However, the widening operating loss and slight decrease in Adjusted EBITDA suggest ongoing investments in growth initiatives.

AtriCure has raised its full-year 2024 revenue guidance to $456 million to $461 million, reflecting confidence in continued growth. The projected 34% to 49% increase in full-year 2024 Adjusted EBITDA is particularly encouraging, suggesting improving profitability alongside revenue growth.

While the company continues to invest in clinical initiatives and new product introductions, investors should monitor the balance between growth investments and profitability improvement in the coming quarters.

Medical Research Analyst

AtriCure's Q2 2024 results highlight the company's strong position in the atrial fibrillation (Afib) treatment market. The accelerated growth in pain management and appendage management products indicates increasing adoption of AtriCure's innovative technologies among physicians.

Key product developments include:

• Continued success of cryoSPHERE® probes for post-operative pain management
• Strong performance of the AtriClip® Flex·V® device in appendage management
• Growth in ENCOMPASS® clamp sales for open ablation procedures

The company's focus on clinical initiatives, particularly the LeAAPS™ stroke reduction trial, demonstrates a commitment to expanding the evidence base for its therapies. This could potentially lead to broader adoption and market expansion in the future.

The introduction of new products, including two cryoSPHERE® probes with reduced freeze times and a smaller profile AtriClip® device, shows AtriCure's dedication to continuous innovation. These advancements could further strengthen the company's competitive position and drive future growth.

AtriCure's diverse product portfolio, addressing Afib treatment, left atrial appendage management and post-operative pain management, provides multiple growth avenues. The strong international growth (29.4%) suggests successful market penetration beyond the U.S., which could be a significant driver of future expansion.

However, investors should note the slight decrease in gross margin, which may indicate pricing pressures or shifts in product mix. Monitoring the adoption rates of newer products and their impact on overall profitability will be important in assessing AtriCure's long-term growth potential in the medical device market.

• Worldwide revenue of $116.3 million – an increase of 15.2% year over year
• Positive cash flow generation of $8.1 million in second quarter 2024

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results.

“Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip^® franchises, as we continued to deliver exceptional patient outcomes across all therapies, while driving positive cash flow,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “Entering the second half of 2024, we are advancing several clinical initiatives including our LeAAPS™ stroke reduction trial and introducing new products across our markets, with two cryoSPHERE^® probes to reduce freeze times and the most advanced, smallest profile AtriClip^® device. We also remain focused on improving the efficiency of our business.”

Second Quarter 2024 Financial Results

Revenue for the second quarter 2024 was $116.3 million, an increase of 15.2% over second quarter 2023 revenue (15.4% on a constant currency basis), reflecting continued adoption of our products by physicians globally and an acceleration in U.S. pain management and international franchises, as well as U.S. open appendage management which outpaced overall growth. On a sequential basis, worldwide revenue for the second quarter 2024 increased approximately 7% from the first quarter.

U.S. revenue was $95.5 million, an increase of $10.6 million or 12.5%, compared to the second quarter 2023. U.S. revenue growth was driven by sales across key product lines, highlighted by cryoSPHERE^® probes for post-operative pain management, the AtriClip^® Flex·V^® device in appendage management, and the ENCOMPASS^® clamp in open ablation. International revenue increased $4.7 million or 29.4% (30.4% on a constant currency basis) to $20.7 million, realizing significant growth across all franchises and most major geographic regions.

Gross profit for the second quarter 2024 was $86.8 million compared to $77.1 million for the second quarter 2023. Gross margin was 74.7% for the second quarter 2024, a decrease of 168 basis points from the second quarter 2023, reflecting less favorable geographic and product mix, as well as increased product costs compared to the prior year. Loss from operations for the second quarter 2024 was $7.2 million, compared to $4.1 million for the second quarter 2023. Basic and diluted net loss per share was $0.17 for the second quarter 2024, compared to $0.11 for the second quarter 2023.

Adjusted EBITDA for the second quarter 2024 is $7.8 million, a decrease of $0.2 million from second quarter of 2023. Adjusted loss per share for the second quarter 2024 was $0.17, compared to $0.12 for the second quarter 2023.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release.

2024 Financial Guidance

AtriCure now expects full year 2024 revenue of approximately $456 million to $461 million, reflecting growth of approximately 15% at the midpoint of the range. Management continues to expect full year 2024 Adjusted EBITDA of approximately $26 million to $29 million, with improvements annually thereafter. Projected full year 2024 adjusted EBITDA represents a 34% to 49% increase over full year 2023. Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.82.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 30, 2024 to discuss second quarter 2024 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly known as Twitter) @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/forward-looking-statements as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of July 30, 2024. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as net income (loss) before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible assets, debt extinguishment and legal settlements. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)
(Unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
United States Revenue:
Open ablation	$	30,760			$	27,002			$	60,060			$	52,144
Minimally invasive ablation		11,828				11,370				24,146				21,007
Pain management		15,006				12,590				27,745				23,658
Total ablation		57,594				50,962				111,951				96,809
Appendage management		37,945				33,941				73,837				66,283
Total United States		95,539				84,903				185,788				163,092
International Revenue:
Open ablation		9,170				7,722				17,072				15,008
Minimally invasive ablation		1,764				1,375				3,878				3,242
Pain management		1,241				439				2,178				667
Total ablation		12,175				9,536				23,128				18,917
Appendage management		8,555				6,479				16,204				12,403
Total International		20,730				16,015				39,332				31,320
Total revenue		116,269				100,918				225,120				194,412
Cost of revenue		29,425				23,841				57,008				47,726
Gross profit		86,844				77,077				168,112				146,686
Operating expenses:
Research and development expenses		20,416				17,438				40,261				32,765
Selling, general and administrative expenses		73,596				63,783				145,936				123,847
Total operating expenses		94,012				81,221				186,197				156,612
Loss from operations		(7,168	)			(4,144	)			(18,085	)			(9,926	)
Other expense, net		(587	)			(881	)			(2,756	)			(1,497	)
Loss before income tax expense		(7,755	)			(5,025	)			(20,841	)			(11,423	)
Income tax expense		253				93				436				171
Net loss	$	(8,008	)		$	(5,118	)		$	(21,277	)		$	(11,594	)
Basic and diluted net loss per share	$	(0.17	)		$	(0.11	)		$	(0.45	)		$	(0.25	)
Weighted average shares used in computing net loss per share:
Basic and diluted		46,909				46,266				46,814				46,187

ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands)
(Unaudited)
	June 30, 2024				December 31, 2023
Assets
Current assets:
Cash, cash equivalents, and short-term investments	$	114,020			$	137,285
Accounts receivable, net		55,568				52,501
Inventories		73,654				67,897
Prepaid and other current assets		9,610				8,563
Total current assets		252,852				266,246
Property and equipment, net		42,175				42,435
Operating lease right-of-use assets		4,030				4,324
Goodwill and intangible assets, net		295,019				298,767
Other noncurrent assets		3,197				2,160
Total Assets	$	597,273			$	613,932
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	58,684			$	72,036
Current lease liabilities		2,541				2,533
Total current liabilities		61,225				74,569
Long-term debt		61,865				60,593
Finance and operating lease liabilities		10,910				11,368
Other noncurrent liabilities		1,188				1,234
Total Liabilities		135,188				147,764
Stockholders' Equity:
Common stock		49				48
Additional paid-in capital		840,939				824,170
Accumulated other comprehensive loss		(569	)			(993	)
Accumulated deficit		(378,334	)			(357,057	)
Total Stockholders' Equity		462,085				466,168
Total Liabilities and Stockholders' Equity	$	597,273			$	613,932

ATRICURE, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS
(In Thousands)
(Unaudited)
Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Net loss, as reported	$	(8,008	)		$	(5,118	)		$	(21,277	)		$	(11,594	)
Income tax expense		253				93				436				171
Other expense, net		587				881				2,756				1,497
Depreciation and amortization expense		4,527				3,580				8,979				6,523
Share-based compensation expense		10,391				8,995				19,656				17,755
Gain from legal settlements		—				(412	)			—				(4,412	)
Non-GAAP adjusted income (adjusted EBITDA)	$	7,750			$	8,019			$	10,550			$	9,940

Reconciliation of Non-GAAP Adjusted Loss Per Share
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Net loss, as reported	$	(8,008	)		$	(5,118	)		$	(21,277	)		$	(11,594	)
Loss on debt extinguishment		—				—				1,362				—
Gain from legal settlements		—				(412	)			—				(4,412	)
Non-GAAP adjusted net loss	$	(8,008	)		$	(5,530	)		$	(19,915	)		$	(16,006	)
Basic and diluted adjusted net loss per share	$	(0.17	)		$	(0.12	)		$	(0.43	)		$	(0.35	)
Weighted average shares used in computing adjusted net loss per share
Basic and diluted		46,909				46,266				46,814				46,187

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730357938/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com



Marissa Bych

Gilmartin Group

Investor Relations

(415) 937-5402

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

What was AtriCure's (ATRC) revenue for Q2 2024?

AtriCure's worldwide revenue for Q2 2024 was $116.3 million, representing a 15.2% increase year-over-year.

How much cash flow did AtriCure (ATRC) generate in Q2 2024?

AtriCure generated positive cash flow of $8.1 million in the second quarter of 2024.

What is AtriCure's (ATRC) updated revenue guidance for full-year 2024?

AtriCure updated its full-year 2024 revenue guidance to approximately $456 million to $461 million, reflecting growth of about 15% at the midpoint of the range.

What was AtriCure's (ATRC) net loss per share in Q2 2024?

AtriCure reported a basic and diluted net loss per share of $0.17 for the second quarter of 2024.

How did AtriCure's (ATRC) international revenue perform in Q2 2024?

AtriCure's international revenue increased by 29.4% to $20.7 million in Q2 2024, showing significant growth across all franchises and most major geographic regions.